Skip to main content

Table 2 Association between aspirin use after diagnosis and CRC-specific and overall survival in patients with colorectal cancer

From: Low-dose aspirin use and survival in colorectal cancer: results from a population-based cohort study

  Mortality Patients Person years Unadjusted HR
(95% CI)
P value Adjusteda HR
(95% CI)
P value
CRC-specific survival
 Aspirin non-user 729 5881 15,957 1.00 (ref. cat.)   1.00 (ref. cat.)  
 Aspirin user 335 2510 6178 1.22 (1.07, 1.39) 0.003 1.17 (1.00, 1.36) 0.06
 1 to 365 DDDs vs. non-user 160 725 2549 1.34 (1.12, 1.59) 0.001 1.23 (1.02, 1.50) 0.03
  ≥ 365 DDDs vs. non-user 175 1785 3629 1.12 (0.95, 1.33) 0.18 1.10 (0.90, 1.33) 0.36
Overall survival
 Aspirin non-user 1035 5881 15,957 1.00 (ref. cat.)   1.00 (ref. cat.)  
 Aspirin user 600 2510 6178 1.51 (1.37, 1.67) < 0.001 1.21 (1.07, 1.37) 0.002
 1 to 365 DDDs vs. non-user 263 725 2549 1.59 (1.39, 1.83) < 0.001 1.26 (1.08, 1.46) 0.004
  ≥ 365 DDDs vs. non-user 337 1785 3629 1.45 (1.28, 1.65) < 0.001 1.18 (1.02, 1.37) 0.03
  1. Abbreviations: CI confidence interval, CRC colorectal cancer, DDD daily defined dose, HR hazard ratio
  2. aMultivariable model contains age, sex, year of diagnosis, deprivation, site (colon or rectum), stage, grade, cancer treatment within 6 months (radiotherapy, chemotherapy, surgery), comorbidities (prior to diagnosis, including acute myocardial infarction, congestive heart failure, peripheral vascular disease, cerebral vascular accident, pulmonary disease, peptic ulcer, liver disease, diabetes, renal disease) and statin use (as a time-varying covariate)